Clinical potential of mass spectrometry-based proteogenomics

Cancer genomics research aims to advance personalized oncology by finding and targeting specific genetic alterations associated with cancers. In genome-driven oncology, treatments are selected for individual patients on the basis of the findings of tumour genome sequencing. This personalized approach has prolonged the survival of subsets of patients with cancer. However, many patients do not respond to the predicted therapies based on the genomic profiles of their tumours. Furthermore, studies pairing genomic and proteomic analyses of samples from the same tumours have shown that the proteome contains novel information that cannot be discerned through genomic analysis alone. This observation has led to the concept of proteogenomics, in which both types of data are leveraged for a more complete view of tumour biology that might enable patients to be more successfully matched to effective treatments than they would using genomics alone. In this Perspective, we discuss the added value of proteogenomics over the current genome-driven approach to the clinical characterization of cancers and summarize current efforts to incorporate targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into the clinical laboratory to facilitate clinical proteogenomics.Precision medicine approaches to the treatment of cancer are largely reliant on genomic analysis alone. In this Perspective the authors provide a rationale for the incorporation of analysis of the proteome, which is a rich source of biological heterogeneity, into the treatment and management of patients with cancer.

[1]  S. Carr,et al.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.

[2]  Paul Kearney,et al.  Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules , 2018, Chest.

[3]  Jeffrey R. Whiteaker,et al.  The evolving role of mass spectrometry in cancer biomarker discovery , 2009, Cancer biology & therapy.

[4]  Yassene Mohammed,et al.  PeptidePicker: a scientific workflow with web interface for selecting appropriate peptides for targeted proteomics experiments. , 2014, Journal of proteomics.

[5]  Aravind Subramanian,et al.  Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes* , 2016, Molecular & Cellular Proteomics.

[6]  Christoph H Borchers,et al.  Multiplexed MRM‐based quantitation of candidate cancer biomarker proteins in undepleted and non‐enriched human plasma , 2013, Proteomics.

[7]  Ruedi Aebersold,et al.  Mass spectrometry based targeted protein quantification: methods and applications. , 2009, Journal of proteome research.

[8]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[9]  L. Ferrucci,et al.  A novel, multiplexed targeted mass spectrometry assay for quantification of complement factor H (CFH) variants and CFH‐related proteins 1–5 in human plasma , 2017, Proteomics.

[10]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[11]  Brendan MacLean,et al.  CPTAC Assay Portal: a repository of targeted proteomic assays , 2014, Nature Methods.

[12]  Richard Simon D.Sc. Critical Review of Umbrella, Basket and Platform Designs for Oncology Clinical Trials , 2017 .

[13]  Hasmik Keshishian,et al.  Automated Microchromatography Enables Multiplexing of Immunoaffinity Enrichment of Peptides to Greater than 150 for Targeted MS-Based Assays. , 2016, Analytical chemistry.

[14]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[15]  Michael F. Sharpnack,et al.  Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Juan Antonio Vizcaíno,et al.  The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition , 2016, Nucleic Acids Res..

[17]  Daniel C. Liebler,et al.  Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. , 2017, Gastroenterology.

[18]  Li Ding,et al.  An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer* , 2015, Molecular & Cellular Proteomics.

[19]  H. Rodriguez,et al.  Proteogenomic convergence for understanding cancer pathways and networks , 2014, Clinical Proteomics.

[20]  Eric W Deutsch,et al.  Using PeptideAtlas, SRMAtlas, and PASSEL: Comprehensive Resources for Discovery and Targeted Proteomics , 2014, Current protocols in bioinformatics.

[21]  Andrew N Hoofnagle,et al.  From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry. , 2014, Clinical chemistry.

[22]  William S Hancock,et al.  Multiple enzymatic digestion for enhanced sequence coverage of proteins in complex proteomic mixtures using capillary LC with ion trap MS/MS. , 2003, Journal of proteome research.

[23]  R. Grant,et al.  Absolute Protein Quantification by Mass Spectrometry: Not as Simple as Advertised. , 2017, Analytical chemistry.

[24]  Andrew N Hoofnagle,et al.  Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. , 2008, Clinical chemistry.

[25]  Matthias Mann,et al.  BoxCar acquisition method enables single-shot proteomics at a depth of 10,000 proteins in 100 minutes , 2018, Nature Methods.

[26]  Christina S. Leslie,et al.  Widespread intronic polyadenylation inactivates tumor suppressor genes in leukemia , 2018, Nature.

[27]  R. Reitz,et al.  A Novel Mass Spectrometry–Based Assay for the Accurate Measurement of Thyroglobulin From Patient Samples Containing Antithyroglobulin Autoantibodies , 2012, Journal of Investigative Medicine.

[28]  R. O’Brien,et al.  Constrained selected reaction monitoring: quantification of selected post-translational modifications and protein isoforms. , 2013, Methods.

[29]  D. Bates,et al.  Hallmarks of alternative splicing in cancer , 2014, Oncogene.

[30]  K. Lynch CLSI C62-A: A New Standard for Clinical Mass Spectrometry. , 2016, Clinical chemistry.

[31]  Donald A Berry,et al.  NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  Otto D. Payton,et al.  Implications for Clinical Practice , 1983 .

[33]  M. Washington,et al.  Precision of Multiple Reaction Monitoring Mass Spectrometry Analysis of Formalin-Fixed, Paraffin-Embedded Tissue , 2012, Journal of proteome research.

[34]  Jacob D. Jaffe,et al.  Proteogenomics: Opportunities and Caveats. , 2016, Clinical chemistry.

[35]  George A Calin,et al.  miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. , 2016, Cancer discovery.

[36]  W. Lehmann,et al.  Improving the precision of quantitative bottom-up proteomics based on stable isotope-labeled proteins , 2012, Analytical and Bioanalytical Chemistry.

[37]  D. Chan,et al.  Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures. , 2016, Journal of proteome research.

[38]  I. A. Wani,et al.  Recent Advances and Future Prospects , 2019 .

[39]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[40]  Derek J. Bailey,et al.  Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.

[41]  Virginia Espina,et al.  Reverse phase protein microarrays advance to use in clinical trials , 2010, Molecular oncology.

[42]  Kurt A. Schalper,et al.  Quantitative Measurement of Cancer Tissue Biomarkers in the Lab and in the Clinic , 2014, Laboratory Investigation.

[43]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[44]  Veronika Vidova,et al.  A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. , 2017, Analytica chimica acta.

[45]  Adam A. Margolin,et al.  Assessing the clinical utility of cancer genomic and proteomic data across tumor types , 2014, Nature Biotechnology.

[46]  Mehdi Mesri,et al.  Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. , 2013, Cancer discovery.

[47]  Chris Sander,et al.  Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome , 2016, Cell.

[48]  Tao Liu,et al.  Targeted proteomic assays for quantitation of proteins identified by proteogenomic analysis of ovarian cancer , 2017, Scientific Data.

[49]  Ronald J. Moore,et al.  Nanodroplet processing platform for deep and quantitative proteome profiling of 10–100 mammalian cells , 2018, Nature Communications.

[50]  S. Lemieux,et al.  Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers , 2016, Leukemia.

[51]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[52]  Paul C. Boutros,et al.  Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines , 2017, Genome Medicine.

[53]  D. Jeffery,et al.  US Food and Drug Administration Perspectives on Clinical Mass Spectrometry. , 2016, Clinical chemistry.

[54]  Ruedi Aebersold,et al.  Prediction of colorectal cancer diagnosis based on circulating plasma proteins , 2015, EMBO molecular medicine.

[55]  Bing Zhang,et al.  Protein identification using customized protein sequence databases derived from RNA-Seq data. , 2012, Journal of proteome research.

[56]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[57]  Jouhyun Jeon,et al.  Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer , 2016, Nature Communications.

[58]  A. Letai,et al.  Functional precision cancer medicine—moving beyond pure genomics , 2017, Nature Medicine.

[59]  R. Kurzrock,et al.  Debunking the Delusion That Precision Oncology Is an Illusion. , 2017, The oncologist.

[60]  Samuel H Payne,et al.  Methods, Tools and Current Perspectives in Proteogenomics * , 2017, Molecular & Cellular Proteomics.

[61]  P. Stephens,et al.  A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. , 2014, The oncologist.

[62]  S. Pinto,et al.  Proteogenomics for understanding oncology: recent advances and future prospects , 2016, Expert review of proteomics.

[63]  E. Petricoin,et al.  Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. , 2012, Journal of proteome research.

[64]  M. Eltoweissy,et al.  Issues and challenges , 2019, Justice for Children in the Context of Counter-Terrorism.

[65]  Jeffrey R. Whiteaker,et al.  Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification. , 2011, Clinics in laboratory medicine.

[66]  Bernhard Kuster,et al.  Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present , 2012, Analytical and Bioanalytical Chemistry.

[67]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[68]  Jingchun Zhu,et al.  Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.

[69]  J. Garin,et al.  Isotope dilution strategies for absolute quantitative proteomics. , 2009, Journal of proteomics.

[70]  Yafeng Zhu,et al.  Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow , 2018, Nature Communications.

[71]  G. Siuzdak,et al.  The Expanding Role of Mass Spectrometry in Metabolite Profiling and Characterization , 2005, Chembiochem : a European journal of chemical biology.

[72]  Mark V Ivanov,et al.  Proteogenomics of Malignant Melanoma Cell Lines: The Effect of Stringency of Exome Data Filtering on Variant Peptide Identification in Shotgun Proteomics. , 2018, Journal of proteome research.

[73]  Panoptic Trial Team Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial , 2018 .

[74]  Michael J MacCoss,et al.  Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma* , 2015, Molecular & Cellular Proteomics.

[75]  G. Collins The next generation. , 2006, Scientific American.

[76]  S. Hewitt,et al.  Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. , 2013, The Journal of molecular diagnostics : JMD.

[77]  D. Fenyö,et al.  Proteogenomics from a bioinformatics angle: A growing field. , 2015, Mass spectrometry reviews.

[78]  Shivakumar Keerthikumar,et al.  Proteotypic Peptides and Their Applications. , 2017, Methods in molecular biology.

[79]  D. Chan,et al.  Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges , 2013, Clinical Proteomics.

[80]  C. Stace A growing field , 1988, Nature.

[81]  Vinay Prasad,et al.  Perspective: The precision-oncology illusion , 2016, Nature.

[82]  Andrew N Hoofnagle,et al.  The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. , 2009, Journal of immunological methods.

[83]  T. Gillis,et al.  Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels , 2017, Human molecular genetics.

[84]  Rui Zhao,et al.  Sensitive targeted quantification of ERK phosphorylation dynamics and stoichiometry in human cells without affinity enrichment. , 2015, Analytical chemistry.

[85]  Donald H Chace,et al.  A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. , 2005, Clinical biochemistry.

[86]  P. Forget,et al.  A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research , 2017, Front. Oncol..

[87]  M. Maitland,et al.  Clinical trials in the era of personalized oncology , 2011, CA: a cancer journal for clinicians.

[88]  A. Hoofnagle,et al.  Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. , 2013, Clinical chemistry.

[89]  Jeffrey R. Whiteaker,et al.  Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Enables Multiplex, Quantitative Pharmacodynamic Studies of Phospho-Signaling* , 2015, Molecular & Cellular Proteomics.

[90]  H. Rodriguez,et al.  Collaboration to Accelerate Proteogenomics Cancer Care: The Department of Veterans Affairs, Department of Defense, and the National Cancer Institute's Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) Network , 2017, Clinical pharmacology and therapeutics.

[91]  Lindsay K. Pino,et al.  The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. , 2020, Mass spectrometry reviews.

[92]  Jeffrey R. Whiteaker,et al.  Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues. , 2016, Journal of proteome research.

[93]  Thomas L. Fillmore,et al.  Facile carrier-assisted targeted mass spectrometric approach for proteomic analysis of low numbers of mammalian cells , 2018, Communications Biology.

[94]  Peter Willett,et al.  What is a tutorial , 2013 .

[95]  William A. Flavahan,et al.  Epigenetic plasticity and the hallmarks of cancer , 2017, Science.

[96]  Gary D Bader,et al.  Pathway and network analysis of cancer genomes , 2015, Nature Methods.

[97]  P. Boutros,et al.  Onco-proteogenomics: cancer proteomics joins forces with genomics , 2014, Nature Methods.

[98]  Carolyn R. Bertozzi,et al.  Methods and Applications , 2009 .

[99]  H. Rodriguez,et al.  Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: An NCI‐CPTC initiative perspective , 2010, Proteomics. Clinical applications.

[100]  Christoph H Borchers,et al.  MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum , 2014, Expert review of proteomics.

[101]  Mike Rossner,et al.  Show me the data , 2007, The Journal of cell biology.

[102]  C. Borchers,et al.  An extensive library of surrogate peptides for all human proteins. , 2015, Journal of proteomics.

[103]  R. Sebra,et al.  Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify* , 2017, Molecular & Cellular Proteomics.

[104]  Christopher R Kinsinger,et al.  Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. , 2010, Clinical chemistry.

[105]  Tao Ji,et al.  Effects of Calibration Approaches on the Accuracy for LC–MS Targeted Quantification of Therapeutic Protein , 2014, Analytical chemistry.

[106]  R. Aebersold,et al.  Perspectives of targeted mass spectrometry for protein biomarker verification. , 2009, Current opinion in chemical biology.

[107]  Brian C. Netzel,et al.  First Steps toward Harmonization of LC-MS/MS Thyroglobulin Assays. , 2016, Clinical chemistry.

[108]  Robertson Craig,et al.  Open source system for analyzing, validating, and storing protein identification data. , 2004, Journal of proteome research.

[109]  K. Bloom,et al.  Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Mark Quinn Newfoundland launches judicial inquiry , 2007, Canadian Medical Association Journal.

[111]  Richard D. Smith,et al.  Advances in targeted proteomics and applications to biomedical research , 2016, Proteomics.

[112]  Yassene Mohammed,et al.  MRMAssayDB: an integrated resource for validated targeted proteomics assays , 2018, Bioinform..

[113]  H. West No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data. , 2016, JAMA oncology.

[114]  Richard Z. Liu,et al.  A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer , 2011, Proteomics. Clinical applications.

[115]  Zefeng Wang,et al.  Novel RNA-Affinity Proteogenomics Dissects Tumor Heterogeneity for Revealing Personalized Markers in Precision Prognosis of Cancer. , 2018, Cell chemical biology.

[116]  George Coukos,et al.  Mass spectrometry-based antigen discovery for cancer immunotherapy. , 2016, Current opinion in immunology.

[117]  Susan C. Lipsett,et al.  Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease , 2012, EMBO molecular medicine.

[118]  Sascha Sauer,et al.  PHOXTRACK-a tool for interpreting comprehensive datasets of post-translational modifications of proteins , 2014, Bioinform..

[119]  Jennifer G. Abelin,et al.  The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction , 2018, Proteomics.

[120]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[121]  Jeffrey R. Whiteaker,et al.  Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. , 2016, Clinical chemistry.

[122]  A. Hoofnagle,et al.  Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry. , 2013, The Journal of clinical endocrinology and metabolism.

[123]  S. Carr,et al.  A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease , 2011, Nature Biotechnology.

[124]  J. Chen,et al.  Alternative splicing in cancer: implications for biology and therapy , 2014, Oncogene.

[125]  G. Jarvik,et al.  Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. , 2015, Journal of proteomics.

[126]  Jeffrey R. Whiteaker,et al.  Commercially available antibodies can be applied in quantitative multiplexed peptide immunoaffinity enrichment targeted mass spectrometry assays , 2016, Proteomics.

[127]  Brian C. Netzel,et al.  Usefulness of a thyroglobulin liquid chromatography-tandem mass spectrometry assay for evaluation of suspected heterophile interference. , 2014, Clinical chemistry.

[128]  Jeffrey R. Whiteaker,et al.  Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. , 2007, Analytical biochemistry.

[129]  Heidi Zhang,et al.  Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. , 2007, Journal of proteome research.

[130]  Ruedi Aebersold,et al.  Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics , 2012, Science Translational Medicine.

[131]  Anthony J. Cesnik,et al.  Proteogenomics: Integrating Next-Generation Sequencing and Mass Spectrometry to Characterize Human Proteomic Variation. , 2016, Annual review of analytical chemistry.

[132]  K. Syrigos,et al.  Proof of the Quantitative Potential of Immunofluorescence by Mass Spectrometry , 2016, Laboratory Investigation.

[133]  F. Vandenesch,et al.  Isotope-labeled Protein Standards , 2007, Molecular & Cellular Proteomics.

[134]  Luis Mendoza,et al.  PASSEL: The PeptideAtlas SRMexperiment library , 2012, Proteomics.

[135]  J. Yates,et al.  Isobaric Labeling-Based Relative Quantification in Shotgun Proteomics , 2014, Journal of proteome research.

[136]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[137]  Thomas L. Fillmore,et al.  Deep-Dive Targeted Quantification for Ultrasensitive Analysis of Proteins in Nondepleted Human Blood Plasma/Serum and Tissues. , 2017, Analytical chemistry.

[138]  H. Burstein On Sequencing the Full Genome of a Cancerous Cell , 2009 .

[139]  Ronald J. Moore,et al.  Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.

[140]  Jeffrey R. Whiteaker,et al.  Immobilized Metal Affinity Chromatography Coupled to Multiple Reaction Monitoring Enables Reproducible Quantification of Phospho-signaling* , 2015, Molecular & Cellular Proteomics.

[141]  P. Nuciforo,et al.  High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy , 2015, Molecular oncology.

[142]  Susan E. Abbatiello,et al.  Comprehensive Single-Shot Proteomics with FAIMS on a Hybrid Orbitrap Mass Spectrometer. , 2018, Analytical chemistry.

[143]  Susan E Abbatiello,et al.  Evaluation of Large Scale Quantitative Proteomic Assay Development Using Peptide Affinity-based Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.

[144]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[145]  Ruedi Aebersold,et al.  Proteomics meets the scientific method , 2013, Nature Methods.

[146]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[147]  Adele Bourmaud,et al.  Parallel reaction monitoring using quadrupole‐Orbitrap mass spectrometer: Principle and applications , 2016, Proteomics.

[148]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[149]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[150]  B. Blencowe,et al.  Regulation of Alternative Splicing by Histone Modifications , 2010, Science.

[151]  Pei Wang,et al.  A targeted proteomics–based pipeline for verification of biomarkers in plasma , 2011, Nature Biotechnology.

[152]  Richard Simon,et al.  Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials , 2017, Clinical pharmacology and therapeutics.

[153]  Jeffrey R. Whiteaker,et al.  A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage , 2018, Radiation Research.

[154]  A. Blackler,et al.  Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[155]  Jeffrey R. Whiteaker,et al.  Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry. , 2010, Journal of immunological methods.

[156]  I. Turko,et al.  Quantitative performance of internal standard platforms for absolute protein quantification using multiple reaction monitoring-mass spectrometry. , 2015, Analytical chemistry.

[157]  Pei Wang,et al.  Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins , 2013, Nature Methods.

[158]  Brian C. Netzel,et al.  Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes. , 2015, The Journal of clinical endocrinology and metabolism.

[159]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[160]  M. Cronin,et al.  Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. , 2007, Clinical chemistry.

[161]  D. Lauffenburger,et al.  Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks , 2007, Proceedings of the National Academy of Sciences.

[162]  Li Ding,et al.  Proteogenomic integration reveals therapeutic targets in breast cancer xenografts , 2017, Nature Communications.

[163]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[164]  B. Taylor,et al.  Implementing Genome-Driven Oncology , 2017, Cell.

[165]  Jeffrey R. Whiteaker,et al.  Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. , 2018, DNA repair.

[166]  R. Bischoff,et al.  High-sensitivity LC-MS/MS quantification of peptides and proteins in complex biological samples: the impact of enzymatic digestion and internal standard selection on method performance. , 2013, Analytical chemistry.

[167]  A. Nesvizhskii Proteogenomics: concepts, applications and computational strategies , 2014, Nature Methods.

[168]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[169]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  L. Sokoll,et al.  Antiquated tests within the clinical pathology laboratory. , 2010, The American journal of managed care.

[171]  Bruno Domon,et al.  Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment , 2017, Clinical Cancer Research.

[172]  J. Rüschoff,et al.  Proficiency testing of immunohistochemical biomarker assays in breast cancer , 2008, Virchows Archiv.

[173]  Brendan MacLean,et al.  Panorama: A Targeted Proteomics Knowledge Base , 2014, Journal of proteome research.

[174]  Núria Malats,et al.  Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine. , 2017, Journal of proteome research.

[175]  P. Fitzgibbons,et al.  National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. , 2009, Archives of pathology & laboratory medicine.

[176]  C. Plass,et al.  Genome-wide epigenetic regulation of miRNAs in cancer. , 2013, Cancer research.

[177]  Daniel C. Liebler,et al.  Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction* , 2016, Molecular & Cellular Proteomics.

[178]  H. Karnes,et al.  Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC-MS/MS. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[179]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[180]  Christopher R Kinsinger,et al.  Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. , 2010, Clinical chemistry.